Medindia1d
Pembrolizumab Shows Promise in Soft Tissue Sarcoma Care
More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...
MedPage Today1d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
Clinical trial shows immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
TMCnet1d
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...
EurekAlert!2d
Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...
IO Biotech Announces Participation In Upcoming Investor Conferences
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...